Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease

被引:12
作者
Chen, Cheng [1 ]
Beloqui, Ana [1 ,2 ]
Xu, Yining [3 ,4 ]
机构
[1] Catholic Univ Louvain, UCLouvain, Adv Drug Delivery & Biomat, Louvain Drug Res Inst, B-1200 Brussels, Belgium
[2] WEL Res Inst, Ave Pasteur 6, B-1300 Wavre, Belgium
[3] Sichuan Univ, West China Hosp, Inst Metab Dis & Pharmacotherapy, Dept Pharm, Chengdu 610041, Peoples R China
[4] Sichuan Univ, West China Sch Pharm, Dept Clin Pharm & Pharm Adm, Lab Drug Targeting & Drug Delivery Syst,Educ Minis, Chengdu 610041, Peoples R China
关键词
Oral nanomedicine; Biointeraction; Gastrointestinal tract; Gastrointestinal and extra -gastrointestinal; diseases; INFLAMMATORY-BOWEL-DISEASE; DRUG-DELIVERY SYSTEMS; TYPE-2; DIABETES-MELLITUS; CAUSE MUCOSAL DAMAGE; HELICOBACTER-PYLORI; ULCERATIVE-COLITIS; INTESTINAL BARRIER; GUT MICROBIOTA; TARGETED NANOPARTICLES; EXTRACELLULAR VESICLES;
D O I
10.1016/j.addr.2023.115117
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oral administration is the preferred route of administration based on the convenience for and compliance of the patient. Oral nanomedicines have been developed to overcome the limitations of free drugs and overcome gastrointestinal (GI) barriers, which are heterogeneous across healthy and diseased populations. This review aims to provide a comprehensive overview and comparison of the oral nanomedicine biointeractions in the gastrointestinal tract (GIT) in health and disease (GI and extra-GI diseases) and highlight emerging strategies that exploit these differences for oral nanomedicine-based treatment. We introduce the key GI barriers related to oral delivery and summarize their pathological changes in various diseases. We discuss nanomedicine biointeractions in the GIT in health by describing the general biointeractions based on the type of oral nanomedicine and advanced biointeractions facilitated by advanced strategies applied in this field. We then discuss nanomedicine biointeractions in different diseases and explore how pathological characteristics have been harnessed to advance the development of oral nanomedicine.
引用
收藏
页数:26
相关论文
共 320 条
  • [1] Gut microbiome composition and risk factors in a large cross-sectional IBS cohort
    Agnello, Melissa
    Carroll, Lauren N.
    Imam, Nabeel
    Pino, Rodolfo
    Palmer, Christina
    Varas, Ignacio
    Greene, Claire
    Hitschfeld, Maureen
    Gupta, Sarah
    Almonacid, Daniel E.
    Hoaglin, Michael C.
    [J]. BMJ OPEN GASTROENTEROLOGY, 2020, 7 (01):
  • [2] Immune activation in irritable bowel syndrome: what is the evidence?
    Aguilera-Lizarraga, Javier
    Hussein, Hind
    Boeckxstaens, Guy E.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2022, 22 (11) : 674 - 686
  • [3] Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials
    Aguirre, T. A. S.
    Teijeiro-Osorio, D.
    Rosa, M.
    Coulter, I. S.
    Alonso, M. J.
    Brayden, D. J.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2016, 106 : 223 - 241
  • [4] Micro and nanoscale technologies in oral drug delivery
    Ahadian, Samad
    Finbloom, Joel A.
    Mofidfar, Mohammad
    Diltemiz, Sibel Emir
    Nasrollahi, Fatemeh
    Davoodi, Elham
    Hosseini, Vahid
    Mylonaki, Ioanna
    Sangabathuni, Sivakoti
    Montazerian, Hossein
    Fetah, Kirsten
    Nasiri, Rohollah
    Dokmeci, Mehmet Remzi
    Stevens, Molly M.
    Desai, Tejal A.
    Khademhosseini, Ali
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2020, 157 : 37 - 62
  • [5] Type 2 diabetes
    Ahmad, Ehtasham
    Lim, Soo
    Lamptey, Roberta
    Webb, David R.
    Davies, Melanie J.
    [J]. LANCET, 2022, 400 (10365) : 1803 - 1820
  • [6] The gut-liver axis in liver disease: Pathophysiological basis for therapy
    Albillos, Agustin
    de Gottardi, Andrea
    Rescigno, Maria
    [J]. JOURNAL OF HEPATOLOGY, 2020, 72 (03) : 558 - 577
  • [7] Diet-induced alteration of intestinal stem cell function underlies obesity and prediabetes in mice
    Aliluev, Alexandra
    Tritschler, Sophie
    Sterr, Michael
    Oppenlaender, Lena
    Hinterdobler, Julia
    Greisle, Tobias
    Irmler, Martin
    Beckers, Johannes
    Sun, Na
    Walch, Axel
    Stemmer, Kerstin
    Kindt, Alida
    Krumsiek, Jan
    Tschop, Matthias H.
    Luecken, Malte D.
    Theis, Fabian J.
    Lickert, Heiko
    Boettcher, Anika
    [J]. NATURE METABOLISM, 2021, 3 (09) : 1202 - +
  • [8] Luminal Cysteine-Proteases Degrade Colonic Tight Junction Structure and Are Responsible for Abdominal Pain in Constipation-Predominant IBS
    Annahazi, Anita
    Ferrier, Laurent
    Bezirard, Valerie
    Leveque, Mathilde
    Eutamene, Helene
    Ait-Belgnaoui, Afifa
    Coeffier, Moise
    Ducrotte, Philippe
    Roka, Richard
    Inczefi, Orsolya
    Gecse, Krisztina
    Rosztoczy, Andras
    Molnar, Tamas
    Ringel-Kulka, Tamar
    Ringel, Yehuda
    Piche, Thierry
    Theodorou, Vassilia
    Wittmann, Tibor
    Bueno, Lionel
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (08) : 1322 - 1331
  • [9] Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice
    Annahazi, Anita
    Gecse, Krisztina
    Dabek, Marta
    Ait-Belgnaoui, Afifa
    Rosztoczy, Andras
    Roka, Richard
    Molnar, Tamas
    Theodorou, Vassilia
    Wittmann, Tibor
    Bueno, Lionel
    Eutamene, Helene
    [J]. PAIN, 2009, 144 (1-2) : 209 - 217
  • [10] Recent advances in colon drug delivery systems
    Arevalo-Perez, Roberto
    Maderuelo, Cristina
    Lanao, Jose M.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2020, 327 : 703 - 724